Overview Dividends

(SNDX) Syndax Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87164F1057

Menin Inhibitor, CSF-1R Antibody, HDAC Inhibitor

Biotechnology
Market Cap in USD: 1,805m

IPO / Inception: 2016-03-03
Return 12m vs S&P 500: 42.2%

EPS (Earnings per Share)

EPS CAGR: -38.70%
EPS Trend: -55.9%

Last SUE: 0.08
Qual. Beats: 0

Revenue

Rev. CAGR: -23.71%
Rev. Trend: 48.1%

Last SUE: -0.07
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	55.0%
Value at Risk 5%th	81.2%
Relative Tail Risk	-10.25%

Reward TTM
Sharpe Ratio	1.00
Alpha	44.98
CAGR/Max DD	-0.09

Character TTM
Hurst Exponent	0.561
Beta	1.042
Beta Downside	1.256

Drawdowns 3y
Max DD	69.88%
Mean DD	37.55%
Median DD	34.49%

Description: SNDX Syndax Pharmaceuticals November 15, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) is a commercial-stage biotech focused on oncology, with its lead candidates revumenib (a menin inhibitor) for relapsed/refractory acute leukemias and axatilimab (a CSF-1R antibody) for chronic graft-versus-host disease. The firm is expanding revumenib into mutant NPM1 AML, combination regimens, and metastatic colorectal cancer, while axatilimab is also being evaluated for idiopathic pulmonary fibrosis; it holds a licensing deal with Eddingpharm to develop the HDAC inhibitor entinostat.

Key metrics as of the latest filing (Q3 2024) include a market capitalization of roughly $1.2 billion, cash and equivalents of $210 million giving a runway of about 18 months at current burn, and a 2023-24 R&D spend of $120 million, reflecting heavy investment in late-stage trials. The oncology biotech sector remains sensitive to FDA review timelines and pricing pressures, but a 2023-24 industry-wide increase of ~12 % in venture capital funding for early-stage cancer therapeutics supports continued pipeline financing.

If you want a data-driven, independent view of Syndax’s valuation and risk profile, a deeper dive on ValueRay’s analyst platform could be a useful next step.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-311.6m TTM) > 0 and > 6% of Revenue (6% = 6.69m TTM)

FCFTA -0.56 (>2.0%) and ΔFCFTA 4.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 372.6% (prev 2149 %; Δ -1777 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.56 (>3.0%) and CFO -310.9m > Net Income -311.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (86.6m) change vs 12m ago 1.39% (target <= -2.0% for YES)

Gross Margin 91.60% (prev -169.8%; Δ 261.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 22.82% (prev 3.88%; Δ 18.94pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -10.41 (EBITDA TTM -294.8m / Interest Expense TTM 23.7m) >= 6 (WARN >= 3)

Altman Z'' -10.41

(A) 0.75 = (Total Current Assets 529.8m - Total Current Liabilities 114.2m) / Total Assets 551.8m

(B) -2.61 = Retained Earnings (Balance) -1.44b / Total Assets 551.8m

warn (B) unusual magnitude: -2.61 — check mapping/units

(D) -3.30 = Book Value of Equity -1.44b / Total Liabilities 436.4m

Total Rating: -10.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.55

1. Piotroski 1.50pt

2. FCF Yield -18.33%

3. FCF Margin data missing

4. Debt/Equity 2.99

5. Debt/Ebitda -0.78

7. RoE -160.6%

8. Rev. Trend 48.13%

9. EPS Trend -55.89%

What is the price of SNDX shares?

As of December 30, 2025, the stock is trading at USD 21.07 with a total of 703,335 shares traded.
Over the past week, the price has changed by -1.91%, over one month by +10.20%, over three months by +35.41% and over the past year by +68.29%.

Is SNDX a buy, sell or hold?

Syndax Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SNDX.

Strong Buy: 9
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SNDX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	39.3	86.6%
Analysts Target Price	39.3	86.6%
ValueRay Target Price	24.2	15%

SNDX Fundamental Data Overview December 23, 2025

Market Cap USD = 1.81b (1.81b USD * 1.0 USD.USD)
P/S = 16.2188
P/B = 15.6353
Beta = 0.475
Revenue TTM = 111.6m USD
EBIT TTM = -247.0m USD
EBITDA TTM = -294.8m USD
Long Term Debt = 331.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 23.3m USD (from shortTermDebt, last quarter)
Debt = 345.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 228.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.70b USD (1.81b + Debt 345.4m - CCE 454.2m)
Interest Coverage Ratio = -10.41 (Ebit TTM -247.0m / Interest Expense TTM 23.7m)
FCF Yield = -18.33% (FCF TTM -311.0m / Enterprise Value 1.70b)
FCF Margin = -278.8% (FCF TTM -311.0m / Revenue TTM 111.6m)
Net Margin = -279.3% (Net Income TTM -311.6m / Revenue TTM 111.6m)
Gross Margin = 91.60% ((Revenue TTM 111.6m - Cost of Revenue TTM 9.37m) / Revenue TTM)
Gross Margin QoQ = 86.10% (prev 96.63%)
Tobins Q-Ratio = 3.07 (Enterprise Value 1.70b / Total Assets 551.8m)
Interest Expense / Debt = 0.87% (Interest Expense 3.01m / Debt 345.4m)
Taxrate = 100.0% (out of range, set to none) (-318.8m / -318.8m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 4.64 (Total Current Assets 529.8m / Total Current Liabilities 114.2m)
Debt / Equity = 2.99 (Debt 345.4m / totalStockholderEquity, last quarter 115.4m)
Debt / EBITDA = -0.78 (negative EBITDA) (Net Debt 228.6m / EBITDA -294.8m)
Debt / FCF = -0.74 (negative FCF - burning cash) (Net Debt 228.6m / FCF TTM -311.0m)
Total Stockholder Equity = 194.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.47% (Net Income -311.6m / Total Assets 551.8m)
RoE = -160.6% (Net Income TTM -311.6m / Total Stockholder Equity 194.0m)
RoCE = -46.99% (EBIT -247.0m / Capital Employed (Equity 194.0m + L.T.Debt 331.6m))
RoIC = 1491 % (out of range, set to none) (EBIT -247.0m / (Assets 551.8m - Curr.Liab 114.2m - Cash 454.2m))
WACC = 8.28% (E(1.81b)/V(2.15b) * Re(9.86%) + (debt cost/tax rate unavailable))
Discount Rate = 9.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.29%
Fair Price DCF = unknown (Cash Flow -311.0m)
EPS Correlation: -55.89 | EPS CAGR: -38.70% | SUE: 0.08 | # QB: 0
Revenue Correlation: 48.13 | Revenue CAGR: -23.71% | SUE: -0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.54 | Chg30d=-0.006 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.74 | Chg30d=-0.257 | Revisions Net=+0 | Growth EPS=+43.0% | Growth Revenue=+119.9%

Additional Sources for SNDX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle